Soluble tumour necrosis factor α receptor 2, a serum marker of resistance to the anabolic actions of growth hormone in subjects with HIV disease

Clinical Science

Volumn 102, Issue 1, 2002, Pages 85-90

  Gelato, Marie C ^a   Mynarcik, Dennis ^a   McNURLAN, Margaret A ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

AIDS; Growth hormone; HIV; IGF I; IL 1 receptor antagonist; Muscle protein synthesis; Protein wasting; Soluble TNF receptor 2; TNF

Indexed keywords

GROWTH HORMONE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY WEIGHT DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HORMONAL THERAPY; HORMONE RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LEAN BODY WEIGHT; MALE; METABOLIC DISORDER; PREDICTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RECEPTOR DENSITY; SKELETAL MUSCLE; STIMULUS RESPONSE; WASTING SYNDROME;

ADULT; ANABOLIC AGENTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GROWTH HORMONE; HIV INFECTIONS; HIV WASTING SYNDROME; HUMANS; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MUSCLE PROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR; STATISTICS, NONPARAMETRIC;

EID: 0036176747     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20010141     Document Type: Article

References (21)

1. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy
2. Weight loss as a predictor of survival and disease progression in HIV infection
3. Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of disease
4. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection
5. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial
6. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance
7. Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy
8. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy
9. Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection
10. Effect of recombinant human tumour necrosis factor alpha on protein synthesis in liver, skeletal muscle and skin of rats
11. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model
12. Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1
13. High-dose pentoxifylline in patients with AIDS inhibition of tumor necrosis factor production
14. Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection - Correlations to clinical, immunologic, and virologic parameters
15. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome
16. Tumor necrosis factor and HIV P24 antigen levels in serum of HIV-infected populations
17. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance
18. Requirement of protein kinase C zeta for stimulation of protein synthesis by insulin
19. Transient exposure of human myoblasts to tumor necrosis factor-alpha inhibits serum and insulin-like growth factor-I stimulated protein synthesis
20. Increased mortality associated with growth hormone treatment in critically ill adults
21. Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex